Insulin inhibits changes in the phospholipid profiles in sciatic nerves from streptozocin-induced diabetic rats: a phosphorus-31 magnetic resonance study.
Sciatic nerve phospholipids obtained from insulin-treated streptozocin-induced diabetic, non-treated streptozocin-induced diabetic, and healthy, control male Sprague-Dawley rats after eighteen weeks of diabetes were studied by 31P NMR spectrometry. Eleven phospholipids resonances were identified as follows: Phosphatidic acid (Chemical shift, 0.30 ppm), dihydrosphingomyelin (0.13 ppm), ethanolamine plasmalogen (0.07 ppm), phosphatidylethanolamine (0.03 ppm), phosphatidylserine (-0.05 ppm), sphingomyelin (-0.09 ppm), lysophosphatidylcholine (-0.28 ppm), phosphatidylinositol (-0.30 ppm), alkylacylglycerophosphorylcholine (-0.78 ppm), choline plasmalogen (-0.80 ppm), and phosphatidylcholine (-0.84 ppm). Diabetic rats showed that phosphatidylcholine was significantly elevated (p < 0.05), and ethanolamine plasmalogen and choline plasmalogen were significantly lower when compared with both control and insulin treated rats. The choline ratio (choline-containing phospholipids over noncholine phospholipids) was significantly elevated in the diabetic group, when compared with both control and insulin-treated groups. The ethanolamine ratio (ethanolamine-containing phospholipids over nonethanolamine phospholipids) and the ratio of the ethanolamine ratio over the choline ratio, was significantly elevated in the control and the insulin-treated groups when compared with the diabetic group. The presence of phosphatidic acid and the significance in phosphatidylcholine and ethanolamine plasmalogen, suggested that insulin had a role in the phosphatidylcholine metabolism in the rat nerve.
Driscoll
D M
DM
Magnetic Resonance Laboratory, Chicago College of Osteopathic Medicine, Midwestern University, IL 60615, USA.
Romano
F D
FD
Smith
C A
CA
Meneses
P
P
D000818:Animals; D002794:Choline / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism*; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D010743:Phospholipids / Q000378:metabolism*; D010759:Phosphorus Isotopes; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012015:Reference Standards; D012584:Sciatic Nerve / Q000187:drug effects* / Q000378:metabolism; D012984:Software; D013311:Streptozocin / Q000008:administration & dosage / Q000633:toxicity
D007328:Insulin; D010743:Phospholipids; D010759:Phosphorus Isotopes; D013311:Streptozocin; D002794:Choline